Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...
Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Defense News on MSN22h
Top Army aviators were on routine flight when helo collided with jetHere's what is known about the Black Hawk and its crew that crashed into the American Airlines passenger jet over the Potomac ...
San Francisco-based Dolby Labs has reported that its Q1 revenues were $357 million (€343.8m), a significant 13 per cent ...
H.C. Wainwright & Co. is acting as the exclusive financial advisor to SeaStar Medical in connection with the offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback